Weekend Reading: Current options for treating HCV genotypes 1-4

Weekend Reading: State-of-the-Art Decision Making in HCV Genotypes 1-4 

Good afternoon folks, when a new learning activity is launched with basic information about HCV this blog offers a quick summary and links to the presentation. 

A new Web-based CME presented by IAS–USA; An Intensive Workshop on Evolving Strategies in Viral Hepatitis Management, aired this month in Atlanta, GA. 

Although this learning activity is clinical in nature and directed at physicians, anyone living with HCV and considering treatment has an opportunity to learn more about disease management, testing, methods used to assess fibrosis, current options for treating HCV genotypes 1-4, and more. 

Participants can listen to an audio, or view a slide-set along with the webcast. I highly recommend watching the webcast, it offers an index for navigating through the program. 

Links

1- Begin by clicking, here. 

2- Under "An Intensive Workshop on Evolving Strategies in Viral Hepatitis Management" 

Click on a subject.

3- Decide to either listen or watch the webcast, when clicking on the latter a new page will launch, click on “I have read these instructions and understand them,” at the bottom of the page to begin the activity.

Index 

Learning Objectives

________________________________________________

Welcome and Participant Introductions
Michael S. Saag, MD

Enjoyable, easy listening. 

________________________________________________

What Clinicians Should Know About HCV
Michael S. Saag, MD

________________________________________________

HCV is a LIVER Disease

Kenneth E. Sherman, MD, PhD

________________________________________________

State-of-the-Art Decision Making in Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients

Kenneth E. Sherman, MD, PhD

________________________________________________

Pharmacokinetics and Drug Interactions of Direct-Acting Antivirals (DAAs)
Lucas Hill, PharmD, AAHIVP

Related -  FDA Update - Important safety information: Harvoni , and Sovaldi‏

     
________________________________________________

State-of-the-Art Decision Making in Genotype 2 and 3 Treatment-Naive and Treatment-Experienced Patients: Case-Based Discussion

Michael S. Saag, MD

________________________________________________

Source - IAS–USA; An Intensive Workshop on Evolving Strategies in Viral Hepatitis Management